Current Approaches in Optimizing Targeted Agents and Sequencing Decisions for HR+ Breast Cancer
Medscape,
Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2…
Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2…
Medscape recently asked breast cancer experts how they sequence targeted agents for HR+, HER2/neu-negative (also known as ErbB-2…
By Clinical Content Hub Adam M. Brufsky, MD, PhD, FACPUniversity of Pittsburgh School of Medicine Key Takeaways Approximately…